Christiane M Koller1, Young Kim, Ingo G H Schmidt-Wolf. 1. Department of Internal Medicine III, Center for Integrated Oncology, University Hospital Bonn, 53105 Bonn, Germany. Ingo.Schmidt-Wolf@ukb.uni-bonn.de
Abstract
AIM: Advanced renal cancer has still a very poor prognosis. We combined wingless-related integration site (WNT) inhibitors with a bi-functional peptide, as previous research has proven their individual efficacy in cancer therapy. Each targets cancer cells differently. We wanted to determine whether they have an additive effect. MATERIALS AND METHODS: Our bi-functional peptide consists of a target domain (LTVSPWY) and a lytic domain (KLAKLAK)2. We used three WNT inhibitors: Ethacrinic acid, ciclopirox olamine, piroctone olamine and combined each with the bi-functional peptide. They were tested on three different renal cancer cell lines using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide (MTT) assay. RESULTS: We demonstrated a synergistic effect of WNT inhibitors with the bi-functional peptide. The vitality of cancer cells was reduced significantly (p<0.05), while healthy cells were mostly unaffected. CONCLUSION: The combination of WNT inhibitor and the bi-functional peptide may lead to new treatment options as toxic side-effects can be reduced due to the lower doses of agent required.
AIM: Advanced renal cancer has still a very poor prognosis. We combined wingless-related integration site (WNT) inhibitors with a bi-functional peptide, as previous research has proven their individual efficacy in cancer therapy. Each targets cancer cells differently. We wanted to determine whether they have an additive effect. MATERIALS AND METHODS: Our bi-functional peptide consists of a target domain (LTVSPWY) and a lytic domain (KLAKLAK)2. We used three WNT inhibitors: Ethacrinic acid, ciclopirox olamine, piroctone olamine and combined each with the bi-functional peptide. They were tested on three different renal cancer cell lines using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide (MTT) assay. RESULTS: We demonstrated a synergistic effect of WNT inhibitors with the bi-functional peptide. The vitality of cancer cells was reduced significantly (p<0.05), while healthy cells were mostly unaffected. CONCLUSION: The combination of WNT inhibitor and the bi-functional peptide may lead to new treatment options as toxic side-effects can be reduced due to the lower doses of agent required.
Authors: Scott J Weir; Prasad Dandawate; David Standing; Sangita Bhattacharyya; Prabhu Ramamoorthy; Parthasarathy Rangarajan; Robyn Wood; Amanda E Brinker; Benjamin L Woolbright; Mehmet Tanol; Tammy Ham; William McCulloch; Michael Dalton; Gregory A Reed; Michael J Baltezor; Roy A Jensen; John A Taylor; Shrikant Anant Journal: Cell Death Dis Date: 2021-05-31 Impact factor: 8.469
Authors: Żaneta Piotrowska; Michał Niezgoda; Grzegorz Młynarczyk; Magdalena Acewicz; Irena Kasacka Journal: Front Oncol Date: 2020-11-20 Impact factor: 6.244